This patient’s medical history suggests a diagnosis of acute coronary syndrome. It is important to provide pain relief as soon as possible. This can be achieved by administering GTN (sublingual or buccal), but if there is suspicion of an acute myocardial infarction (MI), intravenous opioids such as morphine should be offered.

Aspirin should be given to all patients with unstable angina or NSTEMI as soon as possible and should be continued indefinitely, unless there are contraindications such as a high risk of bleeding or aspirin hypersensitivity. A single loading dose of 300 mg should be given immediately after presentation.

For patients without a high risk of bleeding and no planned coronary angiography within 24 hours of admission, fondaparinux should be administered. However, if coronary angiography is planned within 24 hours, unfractionated heparin can be offered as an alternative to fondaparinux. For patients with significant renal impairment (creatinine above 265 micromoles per litre), unfractionated heparin should be considered, with dose adjustment based on clotting function monitoring.

Routine administration of oxygen is no longer recommended, but oxygen saturation should be monitored using pulse oximetry as soon as possible, preferably before hospital admission. Supplemental oxygen should only be given to individuals with an oxygen saturation (SpO2) below 94% who are not at risk of hypercapnic respiratory failure, aiming for an SpO2 of 94-98%. For individuals with chronic obstructive pulmonary disease at risk of hypercapnic respiratory failure, a target SpO2 of 88-92% should be achieved until blood gas analysis is available.

Bivalirudin, a specific and reversible direct thrombin inhibitor (DTI), is recommended by NICE as a potential treatment for adults with STEMI undergoing percutaneous coronary intervention.

For more information, refer to the NICE guidelines on the assessment and diagnosis of chest pain of recent onset.

Gout and pseudogout are both characterized by the presence of crystal deposits in the joints that are affected. Gout occurs when urate crystals are deposited, while pseudogout occurs when calcium pyrophosphate crystals are deposited. Under a microscope, these crystals can be distinguished by their appearance. Urate crystals are needle-shaped and negatively birefringent, while calcium pyrophosphate crystals are brick-shaped and positively birefringent.

Gout can affect any joint in the body, but it most commonly manifests in the hallux metatarsophalangeal joint, which is the joint at the base of the big toe. This joint is affected in approximately 50% of gout cases. On the other hand, pseudogout primarily affects the larger joints, such as the knee.

In the UK, the classification of pressure ulcers is done using the international NPUAP-EPUAP system. This particular description refers to a pressure ulcer of grade 2. Please refer to the notes below for more information on the classification of pressure ulcers.

Further Reading:

Pressure ulcers, also known as bedsores, are localized damage to the skin and underlying tissues caused by pressure or pressure combined with shear force. They most commonly occur over bony prominences but can develop on any part of the body. Pressure ulcers develop due to five main factors: pressure, shear, friction, moisture, and circulation and tissue perfusion. Pressure is the most important factor, with intensity and duration playing key roles in the development of pressure ulcers.

Assessment of pressure ulcers in adults should be done using a validated classification tool. The International NPUAP-EPUAP pressure ulcer classification system is preferred in the UK. This system categorizes pressure ulcers into four stages. Stage I is characterized by non-blanchable erythema, which is non-blanchable redness of the skin. Stage II involves partial thickness loss of the dermis, presenting as a shallow open ulcer with a red pink wound bed. Stage III is full thickness skin loss, with subcutaneous fat visible but no exposure of bone, tendon, or muscle. Stage IV is also full thickness tissue loss, but with exposed bone, tendon, or muscle. In addition, some pressure ulcers may be classified as suspected deep tissue injury or unstageable.

Management of pressure ulcers involves general measures such as pressure reducing aids, repositioning, hygiene, cleansing, dressings, analgesia, and dietary optimization. It is also important to optimize or treat underlying health conditions, such as diabetes. For grade 3 and 4 ulcers, additional measures to consider include antibiotics and surgical debridement with or without skin flap coverage.

The initial stage of SJS is characterized by a rash on the skin, specifically on the macular area. As the condition progresses, the rash transforms into blisters, known as bullae, which eventually detach from the skin.

Further Reading:

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous immune reactions characterized by blistering skin rash and erosions/ulceration of mucous membranes. SJS has less than 10% total body surface area (TBSA) involvement, SJS/TEN overlap has 10% to 30% TBSA involvement, and TEN has more than 30% TBSA involvement. The exact cause of SJS and TEN is not well understood, but it is believed to be a T-cell–mediated cytotoxic reaction triggered by drugs, infections, or vaccinations. Drugs are responsible for 50% of SJS cases and up to 95% of TEN cases, with antibiotics and anticonvulsants being the most common culprits.

The clinical features of SJS and TEN include a prodrome of malaise, fever, headache, and cough, followed by the appearance of small pink-red macules with darker centers. These macules can coalesce and develop into larger blisters (bullae) that eventually break and cause the epidermis to slough off. Painful mucosal erosions can also occur, affecting various parts of the body and leading to complications such as renal failure, hepatitis, pneumonia, and urethritis. Nikolsky’s sign, which refers to the easy sloughing off of the epidermal layer with pressure, is a characteristic feature of SJS and TEN.

The diagnosis of SJS, SJS/TEN overlap, and TEN can be confirmed through a skin biopsy, which typically shows desquamation at the epidermal-papillary dermal junction and the presence of necrotic epithelium and lymphocytes. Management of SJS and TEN involves supportive care, withdrawal of the causative agent if drug-related, monitoring for metabolic derangement and infection, maintaining the airway, treating respiratory function and pneumonia, fluid resuscitation, wound care, analgesia, and nutritional support. Ophthalmology consultation is also recommended. Intravenous immunoglobulin, ciclosporin, corticosteroids, and plasmapheresis may be used in treatment, but there is limited evidence supporting their effectiveness.

The prognosis of SJS and TEN can be assessed using the SCORTEN score, which comprises of 7 clinical and biological parameters, with the predicted probability of mortality ranging from 3.2% to 90.0%.

In a clinical setting, the prioritization of patient safety and the safety of staff members is crucial. Violence against other patients and health professionals is not tolerated. However, it is important to consider that the patient in question may be intoxicated or experiencing delirium tremens, which could impair their insight into their own behavior.

To address this situation, it would be wise to call local security as a precautionary measure. This action can serve as a backup if additional assistance is required. However, involving the police at this stage may escalate the situation unnecessarily and potentially agitate the patient further.

Administering sedation to the patient without understanding their medical history or gathering more information would not be appropriate. It is essential to have a comprehensive understanding of the patient’s condition before considering any interventions.

Similarly, asking the patient to leave the department immediately could potentially worsen the situation. It is important to approach the situation with caution and consider alternative strategies to de-escalate the situation effectively.

The most probable causative organism in this case is Streptococcus pneumoniae. This bacterium is a common cause of acute otitis media, especially in young children. It is known to cause infection in the middle ear, leading to symptoms such as ear pain (otalgia), fever, and a red, bulging tympanic membrane. Other organisms such as Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Staphylococcus aureus can also cause ear infections, but Streptococcus pneumoniae is the most likely culprit in this particular case.

Further Reading:

Acute otitis media (AOM) is an inflammation in the middle ear accompanied by symptoms and signs of an ear infection. It is commonly seen in young children below 4 years of age, with the highest incidence occurring between 9 to 15 months of age. AOM can be caused by viral or bacterial pathogens, and co-infection with both is common. The most common viral pathogens include respiratory syncytial virus (RSV), rhinovirus, adenovirus, influenza virus, and parainfluenza virus. The most common bacterial pathogens include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.

Clinical features of AOM include ear pain (otalgia), fever, a red or cloudy tympanic membrane, and a bulging tympanic membrane with loss of anatomical landmarks. In young children, symptoms may also include crying, grabbing or rubbing the affected ear, restlessness, and poor feeding.

Most children with AOM will recover within 3 days without treatment. Serious complications are rare but can include persistent otitis media with effusion, recurrence of infection, temporary hearing loss, tympanic membrane perforation, labyrinthitis, mastoiditis, meningitis, intracranial abscess, sinus thrombosis, and facial nerve paralysis.

Management of AOM involves determining whether admission to the hospital is necessary based on the severity of systemic infection or suspected acute complications. For patients who do not require admission, regular pain relief with paracetamol or ibuprofen is advised. Decongestants or antihistamines are not recommended. Antibiotics may be offered immediately for patients who are systemically unwell, have symptoms and signs of a more serious illness or condition, or have a high risk of complications. For other patients, a decision needs to be made on the antibiotic strategy, considering the rarity of acute complications and the possible adverse effects of antibiotics. Options include no antibiotic prescription with advice to seek medical help if symptoms worsen rapidly or significantly, a back-up antibiotic prescription to be used if symptoms do not improve within 3 days, or an immediate antibiotic prescription with advice to seek medical advice if symptoms worsen rapidly or significantly.

The first-line antibiotic choice for AOM is a 5-7 day course of amoxicillin. For individuals allergic to or intolerant of penicillin, clarithromycin or erythromycin a 5–7 day course of clarithromycin or erythromycin (erythromycin is preferred in pregnant women).

Discitis is an infection that affects the space between the intervertebral discs in the spine. This condition can have serious consequences, including the formation of abscesses and sepsis. The most common cause of discitis is usually Staphylococcus aureus, but other organisms like Streptococcus viridans and Pseudomonas aeruginosa may be responsible in intravenous drug users and those with weakened immune systems. Gram-negative organisms such as Escherichia coli and Mycobacterium tuberculosis can also cause discitis.

There are several risk factors that increase the likelihood of developing discitis. These include having undergone spinal surgery (which occurs in 1-2% of cases post-operatively), having an immunodeficiency, being an intravenous drug user, being under the age of eight, having diabetes mellitus, or having a malignancy.

The typical symptoms of discitis include back or neck pain (which occurs in over 90% of cases), pain that often wakes the patient from sleep, fever (present in 60-70% of cases), and neurological deficits (which can occur in up to 50% of cases). In children, refusal to walk may also be a symptom.

When diagnosing discitis, MRI is the preferred imaging modality due to its high sensitivity and specificity. It is important to image the entire spine, as discitis often affects multiple levels. Plain radiographs are not very sensitive to the early changes of discitis and may appear normal for 2-4 weeks. CT scanning is also not very sensitive in detecting discitis.

Treatment for discitis involves admission to the hospital for intravenous antibiotics. Before starting the antibiotics, it is important to send three sets of blood cultures and a full set of blood tests, including a CRP, to the lab. The choice of antibiotics depends on the specific situation. A typical antibiotic regimen for discitis may include IV flucloxacillin as the first-line treatment if there is no penicillin allergy, IV vancomycin if the infection was acquired in the hospital or there is a high risk of MRSA, and possibly IV gentamicin if there is a possibility of a Gram-negative infection. In cases where there is acute kidney injury and Gram-negative cover is required, IV piperacillin-tazobactam alone may be used.

Multiple myeloma is a cancerous growth of plasma cells, a type of white blood cell responsible for producing antibodies. It is more prevalent in men and typically occurs in individuals over the age of 60.

When a patient over 60 presents with an elevated ESR, unexplained anemia, hypercalcemia, renal impairment, and bone pain, the initial diagnosis is usually multiple myeloma until proven otherwise.

The most common symptoms of multiple myeloma include:

1. Anemia: This is caused by the infiltration of the bone marrow and suppression of blood cell production. It is typically normocytic and normochromic, but can also be macrocytic.

2. Bone pain: Approximately 70% of patients experience bone pain, which commonly affects the spine and ribs. Localized pain and tenderness may indicate a pathological fracture, and vertebral fractures can lead to spinal cord compression.

3. Renal failure: Acute or chronic renal failure occurs in about one-third of patients. This is generally due to the effects of light chains on the tubules.

4. Neurological symptoms: Hypercalcemia can cause weakness, lethargy, and confusion, while hyperviscosity can result in headaches and retinopathy. Amyloid infiltration can lead to peripheral neuropathies, with carpal tunnel syndrome being the most common.

5. Infection: The most common infections seen in multiple myeloma patients are pyelonephritis and pneumonia.

In addition to the routine blood tests already conducted, a suspected diagnosis of multiple myeloma should prompt further investigations, including:

– Plasma viscosity measurement
– Urinary protein electrophoresis to detect Bence-Jones proteins
– Serum electrophoresis to identify the type of paraprotein
– Quantitative immunoglobulin level testing
– Skeletal survey to look for lytic lesions
– Bone marrow aspirate and possibly biopsy

A diagnosis of multiple myeloma is confirmed by the presence of a monoclonal protein in the serum or urine, lytic lesions on X-ray, and an increased number of plasma cells in the bone marrow.

This patient is displaying symptoms and signs that are consistent with a diagnosis of acute pyelonephritis. Additionally, they are showing signs of sepsis, which indicates a more serious illness or condition. Therefore, it would be advisable to admit the patient for inpatient treatment.

According to the recommendations from the National Institute for Health and Care Excellence (NICE), patients with pyelonephritis should be admitted if it is severe or if they exhibit any signs or symptoms that suggest a more serious condition, such as sepsis. Signs of sepsis include significant tachycardia, hypotension, or breathlessness, as well as marked signs of illness like impaired level of consciousness, profuse sweating, rigors, pallor, or significantly reduced mobility. A temperature greater than 38°C or less than 36°C is also indicative of sepsis.

NICE also advises considering referral or seeking specialist advice for individuals with acute pyelonephritis if they are significantly dehydrated or unable to take oral fluids and medicines, if they are pregnant, if they have a higher risk of developing complications due to known or suspected abnormalities of the genitourinary tract or underlying diseases like diabetes mellitus or immunosuppression, or if they have recurrent episodes of urinary tract infections (UTIs).

For non-pregnant women and men, the recommended choice of antibacterial therapy is as follows: oral first-line options include cefalexin, ciprofloxacin, or co-amoxiclav (taking into account local microbial resistance data), and trimethoprim if sensitivity is known. Intravenous first-line options are amikacin, ceftriaxone, cefuroxime, ciprofloxacin, or gentamicin if the patient is severely unwell or unable to take oral treatment. Co-amoxiclav may be used if given in combination or if sensitivity is known. Antibacterials may be combined if there are concerns about susceptibility or sepsis. For intravenous second-line options, it is recommended to consult a local microbiologist.

For pregnant women, the recommended choice of antibacterial therapy is cefalexin for oral first-line treatment. If the patient is severely unwell or unable to take oral treatment, cefuroxime is the recommended intravenous first-line option. If there are concerns about susceptibility or sepsis, it is advised to consult a local microbiologist for intravenous second-line

Von Willebrand disease (vWD) is a common hereditary coagulation disorder that affects approximately 1 in 100 individuals. It occurs due to a deficiency in Von Willebrand factor (vWF), which plays a crucial role in blood clotting. vWF not only binds to factor VIII to protect it from rapid breakdown, but it is also necessary for proper platelet adhesion. When vWF is lacking, both factor VIII levels and platelet function are affected, leading to prolonged APTT and bleeding time. However, the platelet count and thrombin time remain unaffected.

While some individuals with vWD may not experience any symptoms and are diagnosed incidentally during a clotting profile check, others may present with easy bruising, nosebleeds (epistaxis), and heavy menstrual bleeding (menorrhagia). In severe cases, more significant bleeding and joint bleeding (haemarthrosis) can occur.

For mild cases of von Willebrand disease, bleeding can be managed with desmopressin. This medication works by stimulating the release of vWF stored in the Weibel-Palade bodies, which are storage granules found in the endothelial cells lining the blood vessels and heart. By increasing the patient’s own levels of vWF, desmopressin helps improve clotting. In more severe cases, replacement therapy is necessary. This involves infusing cryoprecipitate or Factor VIII concentrate to provide the missing vWF. Replacement therapy is particularly recommended for patients with severe von Willebrand’s disease who are undergoing moderate or major surgical procedures.